European regulators have validated Merck’s application Bavencio for review in kidney cancer. The European Medicines Agency (EMA) has validated Merck’s application for Bavencio (avelumab) for the ...

The decision was based on positive results from the Phase III JAVELIN Renal 101 study. The US Food and Drug Administration (FDA) has approved Merck’s Bavencio (avelumab) plus Inlyta (axitinib) ...

Phase III randomized trial of stereotactic ablative radiotherapy (SAbR) for oligometastatic advanced renal carcinoma (EA8211-SOAR). This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary ...

Merck, known as MSD outside of the United States and Canada, and Eisai announced results from the phase 3 LITESPARK-012 trial evaluating combination regimens for the first-line treatment of patients ...

The US Food and Drug Administration (FDA) has approved Exelixis' Cabometyx (cabozantinib) tablets for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior ...

Kidney cancer, computer illustration. Toripalimab plus axitinib can improve progression-free survival, when compared to sunitinib monotherapy, in patients with treatment-naïve, advanced renal cell ...